ArticleCritical care (London, England)2011
Short term Candida albicans colonization reduces Pseudomonas aeruginosa-related lung injury and bacterial burden in a murine model.
Article in Critical care (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study).Intensive care medicine · 2014Trial
- Candida in the lung: Fact, fiction, friend or foe?PLoS pathogens · 2026Article
- Who arrived first? Priority effects on Candida albicans and Pseudomonas aeruginosa dual biofilms.Communications biology · 2025Article
- Rapid Synergistic Biofilm Production ofInternational journal of molecular sciences · 2022Article
- Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia.Microbial pathogenesis · 2022Article
- Pseudomonas Synergizes with Fluconazole againstInfection and immunity · 2022Article
- Analysis of pathogens and risk factors of secondary pulmonary infection in patients with COVID-19.Microbial pathogenesis · 2021Article
- Microbial Interkingdom Biofilms and the Quest for Novel Therapeutic Strategies.Microorganisms · 2021Review
- Type 3 Innate Lymphoid Cells as Regulators of the Host-Pathogen Interaction.Frontiers in immunology · 2021Review
- Symbiosis and Dysbiosis of the Human Mycobiome.Frontiers in microbiology · 2021Review
- UnravelingFrontiers in cellular and infection microbiology · 2020Article
- Pathogenetic Impact of Bacterial-Fungal Interactions.Microorganisms · 2019Review
- Impact of bronchial colonization with Candida spp. on the risk of bacterial ventilator-associated pneumonia in the ICU: the FUNGIBACT prospective cohort study.Intensive care medicine · 2019Article
- Fungal-Bacterial Interactions in Health and Disease.Pathogens (Basel, Switzerland) · 2019Review
- Review
- Tipping the Balance:Journal of fungi (Basel, Switzerland) · 2018Review
- The best defense is a good (Protease) offense: How Pseudomonas aeruginosa evades mucosal immunity in the lung.Virulence · 2017Article
- Article
- Candida albicans Airway Colonization Facilitates Subsequent Acinetobacter baumannii Pneumonia in a Rat Model.Antimicrobial agents and chemotherapy · 2016Article
- Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways.Journal of visualized experiments : JoVE · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPseudomonas aeruginosa is a frequent cause of ventilator-acquired pneumonia (VAP). Candida tracheobronchial colonization is associated with higher rates of VAP related to P. aeruginosa. This study was designed to investigate whether prior short term Candida albicans airway colonization modulates the pathogenicity of P. aeruginosa in a murine model of pneumonia and to evaluate the effect of fungicidal drug caspofungin.
methodsBALB/c mice received a single or a combined intratracheal administration of C. albicans (1 × 10(5) CFU/mouse) and P. aeruginosa (1 × 10(7) CFU/mouse) at time 0 (T0) upon C. albicans colonization, and Day 2. To evaluate the effect of antifungal therapy, mice received caspofungin intraperitoneally daily, either from T0 or from Day 1 post-colonization. After sacrifice at Day 4, lungs were analyzed for histological scoring, measurement of endothelial injury, and quantification of live P. aeruginosa and C. albicans. Blood samples were cultured for dissemination.
resultsA significant decrease in lung endothelial permeability, the amount of P. aeruginosa, and bronchiole inflammation was observed in case of prior C. albicans colonization. Mortality rate and bacterial dissemination were unchanged by prior C. albicans colonization. Caspofungin treatment from T0 (not from Day 1) increased their levels of endothelial permeability and lung P. aeruginosa load similarly to mice receiving P. aeruginosa alone.
conclusionsP. aeruginosa-induced lung injury is reduced when preceded by short term C. albicans airway colonization. Antifungal drug caspofungin reverses that effect when used from T0 and not from Day 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.